enVVeno Medical Corporation NVNO 深 沪
等待开盘 02-20 09:30:00 美东时间
9.99
+0.380
+3.95%
华盛通- 最 高10.05
- 今 开9.91
- 成交量 5570股
- 最 低 9.33
- 昨 收 9.61
- 总市值 653.63万
- 52周最高 196.70
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 8.67
- 委 比 -81.82%
- 总股本 65.43万
- 历史最高 4935.00
- 量 比 0.47
- 振 幅 7.49%
- 历史最低 9.33
- 每 手 1
- 风险率 57.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多enVVeno Medical Board Approves Reverse Stock Split Of Common Shares At Ratio Of 1 For 35
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for
01-15 21:02
enVVeno Receives Unfavorable Decision From FDA In Response To Supervisory Appeal Of Not-Approvable Letter It Received On August 19 In Response To PMA Application For VenoValve
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from
2025-11-14 06:09
enVVeno Medical Q3 EPS $(0.23) Beats $(0.30) Estimate
enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 34.29 percent increase over losses of $(0.35) per share from
2025-10-31 21:26
enVVeno Medical To File Supervisory Appeal After FDA Rejects VenoValve Premarket Approval Application
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal
2025-09-15 20:47
enVVeno tanks after FDA rejects VenoValve approval
Shares of enVVeno Medical (NASDAQ: NASDAQ:NVNO) plunged on Wednesday after it revealed that the FDA rejected pre-market approval of VenoValve, a surgical replacement venous valve for patients sufferin...
2025-08-20 22:55
enVVeno Medical Announces FDA Not-Approvable Decision On VenoValve PMA Submission
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from
2025-08-20 19:09
enVVeno Medical Corporation Releases Preliminary Findings From VenoValve Health Economic Study Which Indicate That The VenoValve Would Be A Cost-Effective Treatment Option For Patients With Severe Chronic Venous Insufficiency Caused By Deep Valvular Incompetency
Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatmentsThe VenoValve could potentially save $5.9
2025-08-06 20:37
enVVeno Medical reports Q2 results
enVVeno Medical press release (NASDAQ:NVNO): Q2 The Company reported net losses of $6.7 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, representing an increa...
2025-08-01 20:45
enVVeno Medical Corp. Reports Q2 2025 Net Loss Increase of 35% to $6.7 Million Due to Higher Operating Expenses
enVVeno Medical Corp. (NASDAQ:NVNO) reported financial results for the second quarter of 2025, highlighting a net loss of $6.7 million, compared to a net loss of $5.0 million for the same period in 20...
2025-08-01 20:00
enVVeno Medical To Present Interim Two-Year Follow-Up Data On 42 Subjects From 75 Person VenoValve U.S. Pivotal Trial At SVS VAM25
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline83% of subjects maintained a clinically
2025-06-06 20:07
